Treating patients with lung cancer always calls for a focus on informed and shared decision-making, according to expert ...

In modern immunotherapy, modified immune cells are introduced into the body to attack tumors and other targets. Researchers ...

The timing of immunotherapy initiation is not a significant factor in the outcomes of patients with extensive-stage small ...

Inspired by advances in cancer therapy, a team at the Buck Institute has engineered immune cells equipped with specialized ...

BioNTech is buying fellow German mRNA vaccine developer CureVac in an all-stock transaction that values the acquired biotech ...

ICICI Bank, in collaboration with Tata Memorial Centre (TMC), on Thursday announced the commencement of the construction of the Advanced Cancer Care new building at the Homi Bhabha Cancer Hospital and ...

Acquisition will strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapy candidates, marking BioNTech's next key milestone in the execution of its ...

Posters will be available in the publications section of Compugen’s website, www.cgen.com, following presentation.

Data from the ongoing Phase 2a study shows a 100% disease control rate with 45% of patients with advanced cutaneous T-cell lymphoma achieving an objective response:One complete response, three partial ...